Compass Financial Management LLC Makes New $588,000 Investment in Actinium Pharmaceuticals, Inc. $ATNM

Compass Financial Management LLC purchased a new position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 600,230 shares of the company’s stock, valued at approximately $588,000. Compass Financial Management LLC owned 1.91% of Actinium Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Actinium Pharmaceuticals by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock valued at $2,215,000 after purchasing an additional 12,703 shares during the period. AM Investment Strategies LLC bought a new stake in Actinium Pharmaceuticals in the fourth quarter worth about $40,000. Bank of America Corp DE lifted its holdings in Actinium Pharmaceuticals by 76.6% in the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after acquiring an additional 34,176 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Actinium Pharmaceuticals by 278.6% in the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock valued at $102,000 after acquiring an additional 46,545 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new position in shares of Actinium Pharmaceuticals during the 2nd quarter valued at about $70,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Price Performance

NYSE ATNM opened at $1.10 on Monday. Actinium Pharmaceuticals, Inc. has a 12 month low of $0.74 and a 12 month high of $1.81. The company has a market capitalization of $34.59 million, a P/E ratio of -0.79 and a beta of 0.01. The company’s 50 day simple moving average is $0.94 and its 200 day simple moving average is $1.08.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.